- UK price watchdog recommends against Amgen's Lumakras in lung cancerThe UK’s drug pricing watchdog said government reimbursement of Amgen’s lung cancer drug Lumakras should be cut off for new patients. In draft guidance released on Thursday, the National Institut…Endpoints · 18d ago↗ source
- FDA criticizes Lundbeck for webpages on migraine treatment VyeptiThe FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages that made allegedly inflated claims regarding the efficacy of its migraine drug. In an untitled letter sent…Endpoints · 18d ago↗ source
- FDA quietly stops releasing CRLsThe FDA has paused its public release of pharma rejection letters as the agency seeks to avoid litigation around releasing the often sensitive information. The pause follows a law firm in April